12902 Usf Magnolia DrTampa, FL 33612
Fax+1 813-449-8618
Overview of Dr. Bejanyan
Dr. Bejanyan is a Senior Member and Program Leader of the Blood and Marrow Transplant and Cellular Immunotherapy (BMT CI) program, as well as the Head of the Leukemia/Myeloid Section within the BMT and Cellular Immunotherapy Department at Moffitt Cancer Center. She is also a Professor in Oncologic Sciences at the University of South Florida.With extensive clinical and research expertise in BMT and cellular immunotherapies for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), Dr. Bejanyan is dedicated to advancing both clinical and translational research. She focuses on pioneering immune cell therapy strategies to treat leukemia. Dr. Bejanyan is the Principal Investigator (PI) and Co-PI of several cellular immunotherapy clinical trials for AML, including an innovative first-in-human clinical trial using donor-derived, expanded anticancer gamma delta T cells to treat high-risk AML following BMT. In addition to her research contributions, Dr. Bejanyan plays a pivotal role in the broader scientific community. She serves as Co-chair of the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR) and is a member of several esteemed committees, including the International Expert Panel for the AML Relapse Committee, the ASTCT MDS Expert Panel Committee, the BMT CTN Steering Committee, the BMT CTN State of the Science Symposium Myeloid Malignancy Committee, and the CIBMTR Proposal Task Force.
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2009 - 2012- Cleveland Clinic FoundationFellowship, Bone Marrow Failure Diseases , 2008 - 2009
- Cleveland Clinic FoundationResidency, Internal Medicine, 2007 - 2008
St Vincent HospitalResidency, Internal Medicine, 2005 - 2007
Yerevan State Medical UniversityClass of 1999
Certifications & Licensure
FL State Medical License 2017 - 2028
MN State Medical License 2012 - 2018
OH State Medical License 2006 - 2013
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016-2017
Clinical Trials
- Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases Start of enrollment: 2014 Oct 01
- Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant Start of enrollment: 2015 Dec 21
- Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT Start of enrollment: 2017 Jan 24
Publications & Presentations
PubMed
- Expanded antigen-specific donor regulatory T cells for GVHD prevention.Joseph A Pidala, Nicoletta Cieri, Michael J Schell, Xiaofei Song, Yiren Shao
Blood. 2026-06-18 - TA-TMA and GVHD are distinct consequences of endothelial injury: A MIDAS consortium study.Theresa Hahn, Qiuhong Zhao, Elizabeth Greer Miller, Patrick Elder, Lucille Langenberg
Blood Advances. 2026-06-03 - Single center evaluation of a composite risk assessment model to predict non-relapse mortality following allogeneic hematopoietic cell transplantation (HCT).Reshma Ramlal, Jongphil Kim, Zachary Thompson, Leonel Ochoa-Bayona, Asmita Mishra
Bone Marrow Transplantation. 2026-06-01
Journal Articles
- Diffuse Alveolar Hemorrhage Is Most Often Fatal and Is Affected by Graft Source, Conditioning Regiment Toxicity, and Engraftment KineticsErhan H Dincer, Erica D Warlick, Margaret L MacMillan, Patrick Arndt, Daniel J Weisdorf, Nelli Bejanyan, Claudio G Brunstein, Celalettin Ustun, Aleksandr Lazaryan, Ver..., Haematologica
Abstracts/Posters
- Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts OutcomeNelli Bejanyan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Romiplostim Improves Platelet Recovery after UCB TransplantNelli Bejanyan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)Nelli Bejanyan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Personal Loss Plays ‘Profound Role’ in Shaping Doctor’s Career PathJune 12th, 2024
Insurance Accepted
- Aetna Choice POS II
BCBS Blue Card PPO
BCBS Illinois PPO
BCBS Minnesota Blue Cross Accord
CIGNA Open AccessHumana ChoiceCare Network PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
WEA Trust Preferred Provider Plan - Trust Pref - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
